[{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Divestment","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ XOMA"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Midcap Financial Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Midcap Financial Trust","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Midcap Financial Trust"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"APVO711","moa":"PD-L1\/CD40","graph1":"Oncology","graph2":"Preclinical","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Aptevo Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The proceeds will be used for the advancement of its APVO436 (mipletamig), a bispecific CD3xCD123 ADAPTIR molecule that is designed to redirect the patients' immune system to destroy leukemia cells.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 20, 2025

                          Lead Product(s) : Mipletamig

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Roth Capital Partners

                          Deal Size : $8.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The proceeds will be used for the advancement of its mipletamig, a bispecific CD3xCD123 ADAPTIR molecule that is designed to redirect the patients' immune system to destroy leukemia cells.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 18, 2025

                          Lead Product(s) : Mipletamig

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Roth Capital Partners

                          Deal Size : $8.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition, being investigated for various solid tumors.

                          Product Name : APVO711

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 08, 2025

                          Lead Product(s) : APVO711

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The net proceeds from the offering will be used to advance the clinical development of APVO436 (mipletamig), being evaluated for the treatment of Acute Myeloid Leukemia.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 22, 2025

                          Lead Product(s) : Mipletamig

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Jade Biosciences

                          Deal Size : $2.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The net proceeds from the offering will be used to advance the clinical development of APVO436 (mipletamig), being evaluated for the treatment of Acute Myeloid Leukemia.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 21, 2025

                          Lead Product(s) : Mipletamig

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Roth Capital Partners

                          Deal Size : $2.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The net proceeds from the offering will be used to fund the clinical development of APVO436 (mipletamig), which is being evaluated in the early-stage for the treatment of Acute Myeloid Leukemia.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 04, 2025

                          Lead Product(s) : Mipletamig,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Roth Capital Partners

                          Deal Size : $2.1 million

                          Deal Type : Public Offering

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : APVO436 (mipletamig) is a CD3/123 bispefic antibody, currently being evaluated for the treatment of Acute Myeloid Leukemia, in combination with venetoclax and azacitidine.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 12, 2024

                          Lead Product(s) : Mipletamig,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : APVO436 (mipletamig) is a CD3/123 bispefic antibody, currently being evaluated for the treatment of Acute Myeloid Leukemia, in combination with venetoclax and azacitidine.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 20, 2024

                          Lead Product(s) : Mipletamig,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The company intends to use the net proceeds from the offering for the continued clinical development of its product candidate APVO436 for the treatment of acute myeloid leukemia.

                          Product Name : APVO436

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 04, 2024

                          Lead Product(s) : Mipletamig

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Roth Capital Partners

                          Deal Size : $4.6 million

                          Deal Type : Public Offering

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : ALG.APV-527 is a bispecific antibody targeting the 4-1BB receptor on immune cells, being evaluated for solid tumors in the ADAPTIR™ format with a silenced IgG1 Fc domain.

                          Product Name : ALG.APV-527

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 04, 2024

                          Lead Product(s) : ALG.APV-527

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Alligator Bioscience

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank